EURACTIV - Professor Peter Piot, Belgium's special advisor to European Commission president Ursula von der Leyen for European and Global Health Security, has called antimicrobial resistance (AMR) a crisis already underway and gaining importance. Read more
EURACTIV - Europe must work to protect its biotech leadership capability, Belgian Prime Minister Alexander De Croo told Euractiv. Amidst fierce competition from the US and China, De Croo's vision aligns with the European Commission's ambitions for strengthening the sector, citing the Belgian Health & Biotech Valley as the example to follow. Read...
EURACTIV - Within a year, Europe will implement a uniform, pan-EU framework under the new Health Technology Assessment Regulation (HTAR). Concerns remain about stakeholders' readiness and administrative complexities. Read more
EURACTIV - The EFPIA HTA Working Group's Inka Heikkinen and James Ryan spoke with Euractiv's Nicole Verbeeck, giving insights on moving towards a robust HTA system – one that serves patients, industry and progress in Europe or member states. Read more
EURACTIV - The European Parliament's ENVI committee is scheduled to convene today, 19 March, to discuss the new pharmaceutical framework and vote on the compromised text regarding the draft regulation and the revised directive. Read more
EURACTIV - The collaborative efforts of Belgian Health Minister Frank Vandenbroucke and MEP Tomislav Sokol have brought Europe's ambition to establish a European Health Data Space (EHDS) to a pivotal moment, culminating in a provisional agreement empowering patients and researchers with health data. Read more
EURACTIV - Belgian MEP Frederique Ries has proposed tailoring market exclusivity periods for orphan drugs to foster innovation, advocating a 12-year exclusivity period for orphan drug indications lacking authorised medicinal products in the EU. Read more
EURACTIV - Despite Belgium's prominent position as Europe's second-largest biotech industry and its significant achievements in medical innovation, the pursuit of fast and sustainable access to life-saving therapies remains problematic, for Belgium and Europe. Read more
EURACTIV - Belgium aims to double its cancer survival rate by 2040 relying on the nation's current cancer plan, despite calls from pharmaceutical firms for a new strategy. Belgian Health Minister Vandenbroucke said that implementing the existing strategy is preferable to drafting a new national plan. Read more
EURACTIV - Revision of the EU's pharmaceutical legislation remains the health priority for the Belgian presidency of the Council of the EU, but Belgium's efforts to complete the text remain challenged by the complexity of innovation incentives and medicines shortages. Read more